Synchronous liver metastasis is on the rise, impacting surgical decisions and outcomes for various cancers.

• 6% of cancer patients developed synchronous liver metastasis between 2010 and 2021, with a 2.24% annual increase in the early years.
• Nearly 47.5% of cases were oligometastatic, leading to significantly better survival rates with surgery (5-year survival: 41% vs. 7.4%).

Understanding these trends can help tailor patient selection for surgical interventions, especially in oligometastatic cases.

• Colorectal, pancreatic, and small intestine cancers are notable for higher rates of oligometastatic liver metastasis.